MedImmune, Abpro’s Unspecific Plans For Bispecific Antibody Collaboration

The AstraZeneca affiliate and the Boston-area synthetic biology specialist are creating a spinout to develop a bispecific antibody targeting Ang2 and VEGF for undisclosed indications. Cancer and wet age-related macular degeneration seem likely areas of focus.